Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Dow
Harvard Business School

Last Updated: January 25, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ABILIFY

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Abilify

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00044655 ↗ Switching Medication to Treat Schizophrenia Completed Icahn School of Medicine at Mount Sinai Phase 4 2001-07-01 This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
NCT00080314 ↗ Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode Completed Otsuka America Pharmaceutical Phase 3 2004-01-01 The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abilify

Condition Name

Condition Name for Abilify
Intervention Trials
Schizophrenia 61
Bipolar Disorder 25
Major Depressive Disorder 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Abilify
Intervention Trials
Schizophrenia 63
Disease 52
Bipolar Disorder 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Abilify

Trials by Country

Trials by Country for Abilify
Location Trials
United States 588
Canada 25
United Kingdom 21
Korea, Republic of 18
South Africa 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Abilify
Location Trials
California 40
New York 39
Texas 33
Ohio 29
Florida 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Abilify

Clinical Trial Phase

Clinical Trial Phase for Abilify
Clinical Trial Phase Trials
Phase 4 66
Phase 3 44
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Abilify
Clinical Trial Phase Trials
Completed 122
Terminated 15
Unknown status 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Abilify

Sponsor Name

Sponsor Name for Abilify
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 41
Bristol-Myers Squibb 30
Otsuka America Pharmaceutical 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Abilify
Sponsor Trials
Other 137
Industry 127
NIH 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
AstraZeneca
Merck
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.